<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">33531984</PMID>
      <DateRevised>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1837-9664</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Journal of Cancer</Title>
          <ISOAbbreviation>J Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>GTW inhibits the Epithelial to Mesenchymal Transition of Epithelial Ovarian Cancer via ILK/AKT/GSK3β/Slug Signalling Pathway.</ArticleTitle>
        <Pagination>
          <StartPage>1386</StartPage>
          <EndPage>1397</EndPage>
          <MedlinePgn>1386-1397</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.7150/jca.52418</ELocationID>
        <Abstract>
          <AbstractText><b>Background:</b> Epithelial ovarian cancer (EOC) accounts for the most lethal of all gynaecological cancers which is attributed to metastasis, invasiveness and drug resistance. A crucial link has been found between epithelial-mesenchymal transition (EMT) and cancer metastasis and chemo-resistance. Previous studies have confirmed that one of the main components of <i>tripterygium</i> glycosides (GTW)-triptolide (TPL) has anticancer effects. <b>Methods:</b> The purpose of this study is to determine whether GTW could inhibit EMT in A2780/DPP cells <i>in vitro</i> and <i>in vivo</i>, and explore the underlying mechanism. <b>Results:</b> <i>In vitro</i> results showed that GTW inhibited cell proliferation, invasion and migration, and intensified the sensitivity of A2780/DDP cells to cisplatin (DDP). GTW, especially GTW+DDP, significantly inhibited the expression of N-cadherin, integrin-linked kinase (ILK), phospho-protein kinase B/AKT (PKB/p-AKT), phospho-glycogen synthase kinase (p-GSK3β) and Slug, while it increased E-cadherin levels by inhibiting EMT via the ILK/AKT/GSK3β/Slug signalling pathway. Animal results indicated that GTW, especially GTW+DDP, significantly reduced tumour burden, prolonged the life span of mice, and down-regulated the levels of tumour markers CA125 and HE4 by regulating EMT through the ILK/AKT/GSK3β/Slug signalling pathway. <b>Conclusion:</b> Our results highlighted the significance of EMT in EOC metastasis, invasiveness and resistance to DDP and investigated the potential role of GTW as an adjuvant therapeutic agent in chemo-resistant EOC.</AbstractText>
          <CopyrightInformation>© The author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Le</LastName>
            <ForeName>Fuyin</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Puyuan</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Yanying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhan</LastName>
            <ForeName>Fuliang</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Genhua</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Tingtao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, PR China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Translational Medicine, Nanchang University, Nanchang, Jiangxi 330031, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tan</LastName>
            <ForeName>Buzhen</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics &amp; Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>01</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Cancer</MedlineTA>
        <NlmUniqueID>101535920</NlmUniqueID>
        <ISSNLinking>1837-9664</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">A2780/DDP cells</Keyword>
        <Keyword MajorTopicYN="N">Cisplatin (DDP) resistance</Keyword>
        <Keyword MajorTopicYN="N">ILK/AKT/GSK3β/Slug pathway</Keyword>
        <Keyword MajorTopicYN="N">Tripterygium glycosides (GTW)</Keyword>
        <Keyword MajorTopicYN="N">epithelial ovarian cancer (EOC)</Keyword>
        <Keyword MajorTopicYN="N">epithelial-mesenchymal transition (EMT)</Keyword>
      </KeywordList>
      <CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>58</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33531984</ArticleId>
        <ArticleId IdType="pmc">PMC7847657</ArticleId>
        <ArticleId IdType="doi">10.7150/jca.52418</ArticleId>
        <ArticleId IdType="pii">jcav12p1386</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Coburn SB, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140:2451–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5595147</ArticleId>
            <ArticleId IdType="pubmed">28257597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stephen A, Cannistra M D. Cancer of the ovary. New Engl J Med. 2004;329:1550–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8155119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcus CS, Maxwell GL, Darcy KM, Hamilton CA, McGuire WP. Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. J Cancer. 2014;5:25–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3881218</ArticleId>
            <ArticleId IdType="pubmed">24396495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgan RD, Clamp AR, Evans DGR, Edmondson RJ, Jayson GC. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. Cancer Chemoth Pharm. 2018;81:647–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5854713</ArticleId>
            <ArticleId IdType="pubmed">29464354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24767708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001;478:23–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11406167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wernyj RP, Morin PJ. Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Updat. 2004;7:227–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15533760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohmichi M, Hayakawa J, Tasaka K, Kurachi H, Murata Y. Mechanisms of platinum drug resistance. Trends Pharmacol Sci. 2005;26:113–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15749154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savagner P. The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol. 2010;21(Suppl 7):vii89–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3379967</ArticleId>
            <ArticleId IdType="pubmed">20943648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A. et al. Chemoresistance to paclitaxel induces epithelialmesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 2007;31:277–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17611683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R. et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer. 2006;118:290–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16080193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 2007;14:3629–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17909916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rho JK, Choi YJ, Lee JK, Ryoo BY, Na IIl, Yang SH. et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer. 2009;63:219–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18599154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosano L, Cianfrocca R, Spinella F, Castro VD, Nicotra MR, Lucidi A. et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res. 2011;17:2350–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21220476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du F, Wu X, Liu Y, Wang T, Qi X, Mao Y. et al. Acquisition of paclitaxel resistance via PI3Kdependent epithelialmesenchymal transition in A2780 human ovarian cancer cells. Oncol Rep. 2013;30:1113–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23807572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heldin CH, Vanlandewijck M, Moustakas A. Regulation of EMT by TGFbeta in cancer. FEBS Lett. 2012;586:1959–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22710176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zervas CG, Psarra E, Williams V, Solomon E, Vakaloglou KM, Brown NH. A central multifunctional role of integrin-linked kinase at muscle attachment sites. J Cell Sci. 2011;124:1316–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3065386</ArticleId>
            <ArticleId IdType="pubmed">21444757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaji S, Suzuki A, Kanamori H, Mishima W, Yoshimi R, Takasaki H. et al. Affixin interacts with alpha-actinin and mediates integrin signaling for reorganization of F-actin induced by initial cell-substrate interaction. J Cell Biol. 2004;165:539–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2172344</ArticleId>
            <ArticleId IdType="pubmed">15159419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oloumi A, McPhee T, Dedhar S. Regulation of E-cadherin expression and beta-catenin/Tcf transcriptional activity by the integrin-linked kinase. BBA. 2004;1691:1–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15053919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan C, Hennequart SC, Troussard A, Fazli L, Costello P, Sutton K. et al. Regulation of tumor angiogenesis by integrin-linked kinase (ILK) Cancer Cell. 2004;5:79–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14749128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B-AKT by the integrin-linked kinase. Proc Natl Acad Sci. 1998;95:11211–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC21621</ArticleId>
            <ArticleId IdType="pubmed">9736715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu C, Dedhar S. Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes. J Cell Biol. 2001;55:505–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2198863</ArticleId>
            <ArticleId IdType="pubmed">11696562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren J, Wu X, Liao N, Wang G, Fan C, Liu S. et al. Prevention of postoperative recurrence of Crohn's disease: Tripterygium wilfordii polyglycoside versus mesalazine. J Int Med Res. 2013;41:176–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23569144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P. et al. Comparison of Tripterygium wilfordii Hook F Versus Sulfasalazine in the Treatment of Rheumatoid Arthritis. Ann Intern Med. 2009;151:229–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2938780</ArticleId>
            <ArticleId IdType="pubmed">19687490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Chen W. nterleukin 6 inhibition by triptolide prevents inflammation in a mouse model of ulcerative colitis. Exp Ther Med. 2017;14:2271–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5609133</ArticleId>
            <ArticleId IdType="pubmed">28962154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Shen F, Guan CW, Wang WW, Sun XZ, Fu XL. et al. Activation of Nrf2 Protects Against Triptolide-Induced Hepatotoxicity. Plos One. 2014;9:1–10.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou J, Xi C, Wang W, Fu X, Liang JQ, Qiu Y. et al. Triptolide-induced oxidative stress involved with Nrf2 contribute to cardiomyocyte apoptosis through mitochondrial dependent pathways. Toxicol Lett. 2014;230:454–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25169008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y, Wu S, Zhang Y, Wang L, Guo Y. et al. Antitumor effect of triptolide in T-cell lymphoblastic lymphoma by inhibiting cell viability, invasion, and epithelial-mesenchymal transition via regulating the PI3K/AKT/mTOR pathway. Onco Targets Ther. 2018;11:769–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5815473</ArticleId>
            <ArticleId IdType="pubmed">29483777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong YY, Chen HP, Tan BZ, Yu HH, Huang XS. Triptolide avoids cisplatin resistance and induces apoptosis via the reactive oxygen species/nuclear factor-kappaB pathway in SKOV3(PT) platinum-resistant human ovarian cancer cells. Oncol Lett. 2013;6:1084–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3796418</ArticleId>
            <ArticleId IdType="pubmed">24137468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu H, Luo L, Liu F, Zou D, Zhu S, Tan B. et al. Anti-cancer and Sensibilisation Effect of Triptolide on Human Epithelial Ovarian Cancer. J Cancer. 2016;7:2093–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5118673</ArticleId>
            <ArticleId IdType="pubmed">27877225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang G, Hu H, Zhang Y, Zhu Y, Liu J, Tan B. et al. Triptolide sensitizes cisplatin-resistant human epithelial ovarian cancer by inhibiting the phosphorylation of AKT. J Cancer. 2019;10:3012–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6590046</ArticleId>
            <ArticleId IdType="pubmed">31281478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009;9:167–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19238149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Argenta PA, Um I, Kay C, Harrison D, Faratian D, Sueblinvong T. et al. Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer. Gynecol Oncol. 2013;131:368–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23911795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee TY, Liu CL, Chang YC, Nieh S, Lin YS, Jao SW. et al. Increased chemoresistance via snail-raf kinase inhibitor protein signaling in colorectal cancer in response to a nicotine derivative. Oncotarget. 2016;7:23512–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5029643</ArticleId>
            <ArticleId IdType="pubmed">26992205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurimoto R, Iwasawa S, Ebata T, Ishiwata T, Sekine I, Tada Y. et al. Drug resistance originating from a TGF-beta/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. Int J Oncol. 2016;48:1825–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4809654</ArticleId>
            <ArticleId IdType="pubmed">26984042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan Y, Li D, Li H, Wang L, Tian G, Dong Y. YAP overexpression promotes the epithelial-mesenchymal transition and chemoresistance in pancreatic cancer cells. Mol Med Rep. 2016;13:237–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26572166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3176718</ArticleId>
            <ArticleId IdType="pubmed">20531305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D. et al. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol. 2011;8:27–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21102532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faux MC, Coates JL, Kershaw NJ, Layton MJ, Burgess AW. Independent interactions of phosphorylated beta-catenin with E-cadherin at cell-cell contacts and APC at cell protrusions. Plos One. 2010;5:e14127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2994709</ArticleId>
            <ArticleId IdType="pubmed">21152425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu A, Jie Y, Yao Q, Zhang Y, Mingyan E. Slug Is Associated With Tumor Metastasis and Angiogenesis in Ovarian Cancer. Reprod Sci. 2017;24:291–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27368877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Persad S, Dedhar S. The role of integrin-linked kinase (ILK) in cancer progression. Cancer Metast Rev. 2003;22:375–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12884912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer. 2005;5:51–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15630415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Troussard AA, Costello P, Yoganathan TN, Kumagai S, Roskelley CD, Dedhar S. The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9) Oncogene. 2000;19:5444–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11114721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu L, Zhang S, Hu L, Liu L, Guo W, Zhang J. HMGA1 participates in MHCC97H cell proliferation and invasion through the ILK/Akt/GSK3beta signaling pathway. Mol Med Rep. 2017;16:9287–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5779981</ArticleId>
            <ArticleId IdType="pubmed">29152644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reyes-González JM, Quiñones-Díaz BI, Santana Y, Báez-Vega PM, Soto D, Valiyeva F. et al. Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer. Cancers. 2020;12:880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7226328</ArticleId>
            <ArticleId IdType="pubmed">32260415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q, Tan WH, Che JH, Yuan DD, Zhang LY, Sun YH. et al. 12-HETE facilitates cell survival by activating the integrin-linked kinase/NF-κB pathway in ovarian cancer. Cancer Manag Res. 2018;10:5825–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6248369</ArticleId>
            <ArticleId IdType="pubmed">30510451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma JW, Hung CM, Lin YC, Ho CT, Kao JY, Der T. WayAloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells. Oncotarget. 2016;7:58915–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5312285</ArticleId>
            <ArticleId IdType="pubmed">27391337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu C, Dong T, Li R, Lu J, Wei X, Liu P. Emodin inhibits epithelial to mesenchymal transition in epithelial ovarian cancer cells by regulation of GSK-3beta/beta-catenin/ZEB1 signaling pathway. Oncol Rep. 2016;35:2027–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26820690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pooja T, Karunagaran D. Emodin suppresses Wnt signaling in human colorectal cancer cells SW480 and SW620. Eur J Pharmacol. 2014;742:55–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25205133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Que L, Zhao D, Tang XF, Liu JY, Zhang XY, Zhan YH. et al. Effects of lentivirus-mediated shRNA targeting integrin-linked kinase on oral squamous cell carcinoma in vitro and in vivo. Oncol Rep. 2016;35:89–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26531674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghasemi N, Ghobadzadeh S, Zahraei M, Mohammadpour H, Bahrami S, Ganje MB. et al. HE4 combined with CA125: favorable screening tool for ovarian cancer. Med Oncol. 2014;31:808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24323399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Ogaidi I, Gou H, Aguilar ZP, Guo S, Melconian AK, Al-Kazaz AK. et al. Detection of the ovarian cancer biomarker CA-125 using chemiluminescence resonance energy transfer to graphene quantum dots. Chem Commun (Camb) 2014;50:1344–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24345782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng LE, Qu JY, He F. The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer. Open Med (Wars) 2016;11:125–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5329811</ArticleId>
            <ArticleId IdType="pubmed">28352780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Alla AAA, Abdel Ghaffar HM. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn Pathol. 2013;8:11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3621278</ArticleId>
            <ArticleId IdType="pubmed">23343214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Partheen K, Kristjansdottir B, Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol. 2011;22:244–252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3254843</ArticleId>
            <ArticleId IdType="pubmed">22247801</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
